A Phase I/II Study of Escalated-dose Short-course Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer
This study is aimed at providing further clinical evidence to support or refute the current
understanding of biological sensitivity of prostate cancer to fractionated radiotherapy.
Determining the morbidity and cancer control provided by a 4-week course of treatment will
greatly influence future radiotherapy services for patients with localized prostate cancer.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Alberta Health Services
Canada: Health Canada